A Trial of Grazax in Subjects With Hayfever

A Phase III Trial Assessing the Efficacy and Safety of Grazax in Subjects With Seasonal Grass Pollen Induced Rhinoconjunctivitis With or Without Asthma

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00421655

Enrollment

329

Registered

2007-01-12

Start date

2006-12-31

Completion date

2007-10-31

Last updated

2015-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergy

Brief summary

The trial is performed to evaluate the efficacy and safety of specific immunotherapy with Grazax for treatment of grass pollen induced allergy.

Interventions

DRUGGrazax

Tablets 75,000 SQT and matching placebo. One tablet daily.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* History of grass pollen allergy * Positive skin prick test to grass * Positive specific IgE to grass

Exclusion criteria

* FEV1 \<70% of predicted value

Design outcomes

Primary

Measure	Time frame
Recording of allergy symptoms	Grass pollen season 2007

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 10, 2026